Biotech is coming off an epic few years. The sector soared during the pandemic, with venture capital investment and IPO volumes hitting all-time highs. But recently stock valuations have plummeted,… Read More
Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr… Read More
— The former head of Juno Therapeutics, Hans Bishop, signed on as CEO of Grail, a Bay Area biotech focused on the early detection of cancer. Bishop replaces former Grail… Read More
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing. Backed by ARCH Venture Partners, Flagship… Read More
Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s $9 billion acquisition by biotech giant Celgene, he told GeekWire… Read More
This time last year, Seattle biotech company Juno Therapeutics was on its way to having the first CAR T immunotherapy treatment on the market. But a clinical trial of its… Read More
Juno Therapeutics, which spun out of Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute just three years ago, today issued financial results for the… Read More
Juno Therapeutics, the Seattle-based clinical cancer research firm is doing groundbreaking work in seeking a cure for the disease. CEO Hans Bishop said at the GeekWire Summit on Tuesday that… Read More
Juno Therapeutics missed analyst expectations with its Q3 earnings report on Tuesday, posting a net loss of $47.6 million, or 53 cents per share, on $1.6 million in revenue. Analysts… Read More